About: Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
Creator	Jin, Dong-Yan To, Kelvin Kai-Wang Yuen, Kwok-Yung Chu, Hin Ye, Zi-Wei Yuan, Shuofeng Cai, Jian-Piao Yin, Feifei Cao, Jianli Chan, Fuk-Woo, Jasper Oi, Jessica Tsang, Ling Chik, Kenn, Ka-Heng Hung, Fan-Ngai Liang, Ronghui Tang, Kaiming Chan, Chun-Yiu
Source	Medline; PMC
abstract	The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC(50) at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.3390/v12060628
bibo:pmid	32532085
has license	cc-by
sha1sum (hex)	671482434d3ff0eca070fdb936e7e401be1f8bb6
schema:url	https://doi.org/10.3390/v12060628
resource representing a document's title	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
has PubMed Central identifier	PMC7354423
has PubMed identifier	32532085
schema:publication	Viruses
resource representing a document's body	covid:671482434d3ff0eca070fdb936e7e401be1f8bb6#body_text
is schema:about of	named entity 'They' named entity 'caused' named entity 'assays' named entity 'recombinant' named entity 'chloroquine' named entity 'evaluated' named entity 'LOPINAVIR' named entity 'TYPES' named entity 'INVESTIGATED' named entity '2019' named entity 'expression' named entity 'ongoing' named entity 'lopinavir' named entity 'Avonex' named entity 'virus' named entity 'SREBP-1' named entity 'viral load' named entity 'Qiagen' named entity 'potent' named entity 'potent' named entity 'investigated' named entity 'remdesivir' named entity 'SARS-CoV-2' named entity 'replication cycle' named entity 'antiviral agents' named entity 'antiviral agents' named entity 'SARS-CoV-2' named entity 'AM580' named entity 'SARS-CoV-2' named entity 'micromolar' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'MERS' named entity 'primers' named entity 'house rabbit' named entity 'SARS' named entity 'antiviral agent' named entity 'viral load' named entity 'antiviral agents' named entity 'SARS-CoV-2' named entity 'IFN' named entity 'China' named entity 'Merck' named entity 'SARS-CoV-2' named entity 'fetal bovine serum' named entity 'AM580' named entity 'remdesivir' named entity 'Toll-like receptors' named entity 'antiviral agent' named entity 'viral load' named entity 'HKU' named entity 'RNA' named entity 'Boehringer Ingelheim' named entity 'AM580' named entity 'AM580' named entity 'feline coronavirus' named entity 'viral load' named entity 'glycoproteins' named entity 'viral replication' named entity 'reverse transcription' named entity 'RNA' named entity 'serum' named entity 'lipid biosynthesis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software